Obstructive sleep apnea and severity of NAFLD
The prevalence, risks and costs of NASH
NASH is associated with cardiovascular diseases and cardiovascular mortality. Prof Rosano, UK discusses the prevalence, risks and economic costs of NAFLD and NASH. He sheds lights on the risk of obesity that induces many changes. He also reviews countries with higher prevalence, age characteristics and the incidence and progression of the disease
Read MoreThe prevalence, risks and costs of NASH
NASH is associated with cardiovascular diseases and cardiovascular mortality. Prof Rosano, UK discusses the prevalence, risks and economic costs of NAFLD and NASH. He sheds lights on the risk of obesity that induces many changes. He also reviews countries with higher prevalence, age characteristics and the incidence and progression of the disease
Read More
Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population
Several scores based on easily measurable biochemical and clinical parameters, including the fatty liver index (FLI), hepatic steatosis index (HSI), lipid accumulation product (LAP), and NAFLD liver fat score (LFS), have been developed for the detection of NAFLD.
Read More
Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease
D. Kim et al. (Stanford University School of Medicine, Stanford, California, United States) studied whether physical activity, measured by accelerometer, is associated with all-cause and cardiovascular mortality among individuals with NAFLD.
Read MoreComparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population
Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease
What do we know about the lipid effects of PPARs ?
Prof Sacks, USA summarises what we know about the PPARs lipid effects. If the strongest evidence is with PPAR-alpha agonists for which the main lipid effect is lowering triglycerids, the are interesting information to discuss about PPAR-delta (Seladelpar).
Read More
A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
A panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD.
Read More
From NAFLD to MAFLD: when pathophysiology succeeds
Two new position papers convincingly propose that non-alcoholic fatty liver disease needs a new name — metabolic associated fatty liver disease (MAFLD).
Read More